An AS04-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15-55 years old.

被引：0
|
作者：
Schwarz, T. F.
机构：
[1] Juliusspital, Wurzburg, Germany
[2] GlaxoSmithKline Inc, Rixensart, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：50S / 50S
页数：1
相关论文
共 32 条
  • [31] Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine Administered According to an Alternative Dosing Schedule Compared With the Standard Dosing Schedule in Healthy Women Aged 15 to 25 Years Results From a Randomized Study
    Esposito, Susanna
    Birlutiu, Victoria
    Jarcuska, Pavol
    Perino, Antonio
    Man, Sorin Claudiu
    Vladareanu, Radu
    Meric, Dorothee
    Dobbelaere, Kurt
    Thomas, Florence
    Descamps, Dominique
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (03) : E49 - E55
  • [32] Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years
    Puthanakit, Thanyawee
    Huang, Li-Min
    Chiu, Cheng-Hsun
    Tang, Ren-Bin
    Schwarz, Tino F.
    Esposito, Susanna
    Frenette, Louise
    Giaquinto, Carlo
    McNeil, Shelly
    Rheault, Paul
    Durando, Paolo
    Horn, Michael
    Klar, Maximilian
    Poncelet, Sylviane
    De Simoni, Stephanie
    Friel, Damien
    De Muynck, Benoit
    Suryakiran, Pemmaraju V.
    Hezareh, Marjan
    Descamps, Dominique
    Thomas, Florence
    Struyf, Frank
    JOURNAL OF INFECTIOUS DISEASES, 2016, 214 (04): : 525 - 536
1234